endo-6-carboxybicyclo[2.2.1]heptane-2-one | 860434-14-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: endo-6-carboxybicyclo[2.2.1]heptane-2-one
• 英文别名: (1R,2S,4S)-6-oxobicyclo[2.2.1]heptane-2-carboxylic acid
• CAS: 860434-14-6
• 化学式: C₈H₁₀O₃
• 分子量: 154.166
• InChiKey: RUOYCLYBCGDWPG-JKUQZMGJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  endo-6-carboxybicyclo[2.2.1]heptane-2-one 在 吡啶 、 lithium aluminium tetrahydride 、 potassium carbonate 、 臭氧 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 37.5h， 生成 ((1R,2S,4R,6R)-3''-((tert-butyldiphenylsilyl)oxy)dispiro[bicyclo[2.2.1]heptane-2,3'-[1,2,4]trioxolane-5',1''-cyclohexan]-6-yl)methanol
  参考文献：
  名称：

  [EN] CYCLIC PEROXIDES AS PRODRUGS FOR SELECTIVE DELIVERY OF AGENTS
  [FR] PEROXYDES CYCLIQUES UTILISÉS EN TANT QUE PROMÉDICAMENTS POUR L'ADMINISTRATION SÉLECTIVE D'AGENTS

  摘要：

  Described herein,inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease.

  公开号：

  WO2023049829A2
• 作为产物：
  描述：

  6-bromohexahydro-2H-3,5-methanocyclopenta[b]furan-2-one 在 水 、 sodium hydroxide 作用下， 以89.3 %的产率得到endo-6-carboxybicyclo[2.2.1]heptane-2-one
  参考文献：
  名称：

  [EN] CYCLIC PEROXIDES AS PRODRUGS FOR SELECTIVE DELIVERY OF AGENTS
  [FR] PEROXYDES CYCLIQUES UTILISÉS EN TANT QUE PROMÉDICAMENTS POUR L'ADMINISTRATION SÉLECTIVE D'AGENTS

  摘要：

  Described herein,inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease.

  公开号：

  WO2023049829A2

文献信息

• [EN] THERAPEUTIC AGENTS I<br/>[FR] AGENTS THERAPEUTIQUES I
  申请人：ASTRAZENECA AB

  公开号：WO2005066132A1

  公开（公告）日：2005-07-21

  Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

  化合物的化学式(I)，制备这种化合物的方法，它们在治疗肥胖、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫以及相关疾病，以及神经系统疾病如痴呆症、多发性硬化症、帕金森病、亨廷顿舞蹈症、阿尔茨海默病和与疼痛相关的疾病中的应用，以及含有它们的药物组合物。
• Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
  申请人：ELAN PHARMACEUTICALS, INC.

  公开号：EP1612215A1

  公开（公告）日：2006-01-04

  Disclosed are pyroglutamic acid derivatives and related compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g. human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  本文披露了与VLA-4结合的吡咯烷酸衍生物和相关化合物。其中某些化合物还抑制白细胞粘附，特别是通过VLA-4介导的白细胞粘附。这些化合物在治疗哺乳动物患者（例如人类）的炎症性疾病中非常有用，如哮喘、阿尔茨海默病、动脉粥样硬化、艾滋病痴呆、糖尿病、炎症性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些化合物还可用于治疗多发性硬化等炎症性脑部疾病。
• Stereoselective Cyclotrimerization of Enantiopure Iodonorbornenes Catalyzed by Pd Nanoclusters for <i>C</i>₃ or <i>C</i>_3<i>v</i> Symmetric <i>syn</i>-Tris(norborneno)benzenes
  作者：Shuhei Higashibayashi、A. F. G. Masud Reza、Hidehiro Sakurai

  DOI：10.1021/jo100710h

  日期：2010.7.2

  C3 or C3v symmetric enantiopure syn-tris(norborneno)benzenes with various functional groups were synthesized through Pd-catalyzed cyclotrimerization of enantiopure iodonorbornenes. The generality of Pd-catalyzed cyclotrimerization for syn-tris(norborneno)benzenes were well-demonstrated.

  通过Pd对映体纯的碘基降冰片烯的环三聚反应，合成了具有各种官能团的C 3或C 3 v对称的对映体纯的顺式三（降冰片烯）苯。Pd催化合成的三（norborneno）苯的环三聚反应的普遍性已得到充分证明。
• Steroid sparing agents and methods of using same
  申请人：Lieberburg Ivan

  公开号：US20060004019A1

  公开（公告）日：2006-01-05

  This invention relates generally to methods of treatment of inflammatory bowel diseases (IBD), asthma, multiple schlerosis (MS), rheumatoid arthritis (RA), graft vs. host disease (GVHD), host vs. graft disease, and various spondyloarthropathies, comprising administering a steroid sparing immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.

  本发明涉及治疗炎症性肠病(IBD)、哮喘、多发性硬化症(MS)、类风湿性关节炎(RA)、移植物抗宿主病(GVHD)、宿主抗移植物病以及各种脊柱关节病的方法，包括向需要治疗的患者投予一种节省类固醇的免疫球蛋白或小分子组合物。本发明还涉及治疗这些疾病的联合疗法。
• Therapeutic agents I
  申请人：Evertsson Emma

  公开号：US20070185079A1

  公开（公告）日：2007-08-09

  Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

  化合物的公式(I)，制备这些化合物的过程，它们在治疗肥胖症、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫和相关疾病以及神经系统疾病如痴呆、多发性硬化症、帕金森病、亨廷顿舞蹈症和阿尔茨海默病以及与疼痛有关的疾病中的应用，以及含有它们的制药组合物。